The hypothesis that thrombospondin-1 (TSP-1) can exert opposite effects on angiogenesis depending on the functional status of its domains/fragments was investigated. In the rabbit cornea, TSP-1 inhibited angiogenesis induced by fibroblast growth factor-2 (FGF-2). However, when tested per se, TSP-1 was able to elicit an angiogenic response comparable to that induced by FGF-2. Induction of angiogenesis was dose-dependent (20 ng -2 µg/pellet), was prevented by anti-TSP antibodies or by heat-inactivation of TSP-1, and was not due to inflammatory mediators, to FGF-2 or to TGF-β. Equimolar concentrations of the 25 kDa heparin binding fragment of TSP-1 were even more efficient than the whole molecule, and promoted the angiogenic activity of FGF-2. On the contrary, the 140 kDa fragment of TSP-1 did not induce angiogenesis and turned off the angiogenic response to FGF-2. The 25 kDa fragment and TSP-1, but not the 140 kDa fragment, increased endothelial cell invasiveness and stimulated the production and activation of matrix metalloproteinase-2 (MMP-2). Moreover, the 25 kDa fragment reduced the synthesis of the MMP-2 inhibitor TIMP-2, while the 140 kDa fragment caused a twofold increase in TIMP-2 production and inhibited MMPs stimulation by TSP-1 and FGF-2. We conclude that TSP-1 is a source of smaller mediators of angiogenesis, which affect in an opposite way endothelial cell functions and proteolytic activity, thus resulting in an opposite final effect on angiogenesis.
ngiogenesis is a tightly controlled process. In recent years different families of regulators of angiogenesis, both stimulators and inhibitors, have been discovered and characterized by a molecular point of view (1) . In the case of solid tumors, for example, it is now thought that a shift in the balance between stimulators and inhibitors in favor of the former can trigger the angiogenic switch, allowing tumors to recruit new blood vessels from the surrounding host vasculature, which provide them with a survival advantage (2) . This increased angiogenic activity can result in a gain-of-function event where angiogenic stimulators are induced or up-regulated. The possibility exists also that the imbalance could be due to a decrease in the expression or availability of negative regulators (2) . In this context the role of thrombospondin-1 (TSP-1) is intriguing.
TSP-1, a trimeric 450 kDa glycoprotein, is a matricellular protein that can interact with several matrix components, cell receptors, soluble growth factors and proteolytic enzymes. It is involved in complex processes such as embryogenesis, wound healing, angiogenesis and tumorigenesis (3) (4) (5) .
TSP-1 is primarily produced by activated endothelial cells, fibroblasts, and inflammatory cells or is released by activated platelets (6) (7) (8) . TSP-1 production is controlled by tumor suppressor genes and oncogenes (9, 10) . In experimental models as well as in clinical studies, the loss of TSP-1 production has been associated with the acquisition of an angiogenic phenotype and with tumor progression (6, (11) (12) (13) (14) , while restoration of TSP-1 production prevents angiogenesis and reduces tumor growth (15, 16) .
TSP-1 can be found, in vivo, as a soluble form in body fluids, as an extracellular matrix component of injured and remodeling tissues or in the tumor stroma (17) (18) (19) . The in vivo localization of TSP-1 strongly suggests that the protein is involved in angiogenesis. However, studies aimed to clarify the role of TSP-1 in this process have generated conflicting results (10, 20, 21) . TSP-1 prevents the angiogenic response to fibroblast growth factor-2 (FGF-2) in vitro (22) (23) (24) (25) (26) and in vivo (25, 27) . We and others have demonstrated that TSP-1 binds specifically to angiogenic factors including FGF-2, hepatocyte growth factor (HGF), plateletderived growth factor (PDGF) and transforming growth factor-β (TGF-β) (28) (29) (30) (31) . TSP-1 is also able to stimulate pro-angiogenic activities in endothelial cells. TSP-1 induces endothelial cell adhesion, motility and invasion and production of matrix metalloproteinases (MMPs) (32) . Matrix-bound TSP-1 promotes microvessel formation in rat aorta explants, probably due to the indirect mediation of aortic myofibroblasts (33) . Furthermore, BenEzra et al. (34) have shown that TSP-1 greatly potentiated the angiogenic effect of both FGF-2 and lipopolysaccharide (LPS) in rabbit corneas.
It has been proposed that the multiple functions of TSP-1 might depend on its modular structure (20) . Most of the anti-angiogenic activities of TSP-1 have been located in the 140 kDa carboxy-terminal fragment of TSP-1, in the type I repeats, and, at least for inhibition of motility, shown to occur through the TSP-1 receptor CD36 (26) (27) (28) 35, 36) . None of the inhibitory activities have been attributed to the heparin binding domain of TSP.
In this study we address the hypothesis that TSP-1 can exert opposite effects on angiogenesis depending on which domain/fragment is functional in a given biological setting. We have studied two fragments of TSP-1 (25 and 140 kDa) generated by cleavage of the molecule at a site sensitive to the action of several proteolytic enzymes, including neutrophil elastase, cathepsin G, thrombin, plasmin, trypsin and chymotrypsin (5, 37, 38) , and thus potentially relevant in vivo. The ability of TSP-1 and its two fragments to affect angiogenesis in vivo and endothelial cell functions in vitro has been investigated. Our findings demonstrate the existence of a dual role of TSP-1 in angiogenesis and demonstrate the opposite effect of the pro-angiogenic heparin binding 25 kDa fragment and the anti-angiogenic 140 kDa fragment.
MATERIALS AND METHODS

Reagents
TSP-1 was purified from the supernatants of thrombin-stimulated fresh human platelets by chromatography on gelatin-Sepharose (to remove fibronectin), followed by chromatography on heparin-Sepharose and gel filtration (Sephacryl S-200) of the material eluted with 0.6M NaCl. Fragments were prepared by digesting TSP-1 with thrombin (4 U/ml) for 20 hr at 37°C. Thrombin was inactivated by addition of 2 mM phenylmethylsulfonylfluoride and the cleavage products were separated by chromatography on heparin-Sepharose. Fragments were also prepared by digestion of TSP with chymotrypsin (0.5%, wt/wt). Sodium dodecyl sulfatepolyacrylamide gel electrophoresis (SDS-PAGE) and Coomassie blue staining were used to confirm the identity and purity of TSP-1 and its proteolytic fragments.
Ammonium-sulfate precipitated polyclonal anti-human TSP-1 antibodies were prepared as previously described (28) . Anti FGF-2 monoclonal antibodies were from Upstate Biotechnology (Lake Placid, NY). Pan specific TGF-β antibody was from R&D Systems Europe Ltd, Oxon, UK.
Human recombinant FGF-2 was from PeproTech (Rocky Hill, NJ) or Pharmacia-Upjohn (Nerviano, Italy). The synthetic inhibitor of matrix metalloproteinase BB-94 was provided by British Biotech (Oxford, UK). Heparin and 1,10 Phenanthrolene were from Sigma (St. Louis, MO).
Angiogenesis in vivo: rabbit cornea assay
The angiogenic activity was determined in vivo using the rabbit cornea assay (39) .
Slow release pellets preparation and surgical procedure
Slow-release pellets were prepared under sterile conditions, incorporating the test substances into a casting solution of a ethynyl-vinyl copolymer (Elvax-40, Dupont-De Nemours, Wilmington, DE). In the lower half of New Zealand white rabbit eye (Charles River, Calco, Como, Italy), anesthetized by sodium pentothal (30 mg/kg), either one or two micropockets were surgically produced using a pliable iris spatula. The pellets were implanted in the micropockets.
Experimental design
The effect of TSP-1 or its fragments was tested per se to evaluate their angiogenic potential. In experiments aimed to evaluate the interference of multiple factors, substances were tested either incorporated in the same slow release preparation or in independent pellets implanted in two adjacent pockets surgically produced in the same cornea (40, 41) . Examples of the second experimental setting are: evaluation of the angiogenic activity of TSP-1 or the 25 kDa fragment in the presence of FGF-2 and of anti-FGF-2 antibody and assessment of the effect of TSP-1 or anti-TSP-1 antibody on the neovascular growth induced by FGF-2. The effect of TSP-1 was also assessed in the presence of anti TGF-β antibody coreleased from the same pellet.
Quantification of corneal angiogenesis
Subsequent daily observations of the implants were made with a slit lamp stereomicroscope by two independent operators in blind. An angiogenic response was scored positive according to the scheme previously reported (40) . Angiogenic activity was scored by the number of newly formed vessels and by their growth rate. Data are expressed as angiogenic score calculated as [number of vessels × distance from the limbus] as previously reported (41) .
Histological analysis
Corneas were removed at different times (2, 5 and 10 days) and at the end of the experiment and fixed in formalin. Routine histopathological processing was performed. Sections 5 µm thick were cut next to each pellet. Sections were stained with hematoxylin-eosin. At least 40 sections were examined per cornea.
Release of FGF-2 from the pellet
To evaluate whether the presence of TSP-1 could affect the release of FGF-2 from the pellets, slow release preparations were made with radiolabeled FGF-2. FGF-2 was labeled with 125 I using Iodo-Gen (Pierce, Rockford, IL) to a specific activity of ~1.3 × 10 5 cpm/ng (~2200 cpm/fmol) (28). Labeled FGF-2 (1.2 × 10 6 cpm) was used as a tracer, incorporated in the Elvax pellet together with unlabeled FGF-2 (200 ng), with or without TSP-1 (2 µg), as described above. The pellets were incubated at 37°C in PBS with 0.1% bovine serum albumin (BSA), and the radioactivity associated with the pellet or released in the buffer was measured at different times.
Cell culture
Bovine coronary venular endothelial cells (CVEC) were obtained by a bead-perfusion technique through the coronary sinus as previously reported (42) . Cells were maintained in culture in DMEM supplemented with penicillin and streptomycin and 10% bovine calf serum (FCS) on gelatin-coated dishes, and were used between the 15th and 20th passage.
Human umbilical vein endothelial cells (HUVEC) were isolated from umbilical cord veins and grown on 0.2% gelatin-coated flasks in M199 supplemented with 10% FCS, 10% newborn calf serum, 20 mM HEPES, 6 U/ml heparin, 2 mM glutamine, 50 µg/ml endothelial cell growth factor (crude extract from bovine brain) penicillin and streptomycin. Cells were used between the 3rd and 5th passage.
Bovine aortic endothelial cells (BAEC) were provided by E. Dejana (Mario Negri Institute, Milan, Italy) and grown in DMEM supplemented with 10% FCS. Human adrenal microvascular endothelial cells (HAMEC) were isolated and cultured as described (43) .
Invasion assays
The invasive response of endothelial cells, HUVEC, BAEC and HAMEC to TSP-1 was investigated using the Boyden chambers essentially as described (24, 44) . TSP-1 (25-110 nM) or equimolar amounts of the two fragments were used as the attractants, added to the lower compartment of the chamber. The chamber was then assembled with 8 µm pore size polycarbonate PVP-free Nuclepore filters, coated with a layer of the reconstituted basement membrane Matrigel, 0.5 mg/ml (Becton Dickinson, Bedford, MA).
Endothelial cells were harvested, washed in DMEM 0.1% BSA, resuspended in the same medium at the concentration of 0.5 -1 × 106/ml, and added to the upper compartment of the chamber. After incubation at 37°C for 3 (BAEC) or 6 hr (HUVEC, HAMEC and CVEC), the filters were fixed and stained with Diff-Quik (Merz-Dade, Dudingen, Switzerland), and the migrated cells in 10 high-power fields were counted.
Gelatin zymography
Cells were cultured in 96-well cell culture plates in 10% FCS medium until 90% confluence. Cells were washed with and incubated in serum-free medium. Different concentrations of TSP-1 and fragments were added. After 24 hr incubation the conditioned medium was collected, clarified by centrifugation and assayed for zymography. Conditioned media were subjected to electrophoresis in 8% SDS-PAGE containing 1 mg/ml gelatin under non-denaturing conditions as described (32) . After electrophoresis the gels were washed with 2.5% Triton X-100 to remove SDS and incubated for 48 hr at 37°C in 50 mM Tris buffer containing 200 mM NaCl and 20 mM CaCl2, pH 7.4. The gels were stained with 0.5% Coomassie brilliant blue R-250 in 10% acetic acid and 45% methanol and destained with 10% acetic acid and 45% methanol. Bands of gelatinase activity appeared as transparent areas against a blue background. Gelatinase activity was then evaluated by quantitative densitometry. HT1080 cells were used as standard for the metalloproteinases MMP-2 and MMP-9.
RNA extraction and RT-PCR
RT-PCR was used for quantitating mRNA of tissue inhibitor of metalloproteinase-2 (TIMP-2) expression in CVEC stimulated with TSP-1 and its fragments (45) . Cells were suspended in Ultraspec solution and total RNA was extracted using the RNAzol method (Ultraspec RNA, Biotecx). Reverse transcription of 1 µg of total RNA was carried out and 5 µl of cDNA were used to amplify TIMP-2 with the following primers (sense: TGC AGC TGC TCC CCG GTG CAC, antisense: TTA TGG GTC CTC GAT GTC GAG). GAPDH was amplified as control gene with primers described elsewhere (46) . Following amplification, 20 µl aliquots were electrophoresed in 1% agarose gel and the intensity of the bands was quantified by densitometric analysis as described (46) .
RESULTS
TSP-1 promotes non-inflammatory angiogenesis in vivo by a FGF-2 independent mechanism
Gradient dismission of TSP-1 into the avascular corneal tissue induced a dose-dependent angiogenic response in 100% of the implants, with maximal activity at 2 µg/pellet (100 ng/die approximate daily release into tissue) (Fig. 1A,B) . The capillary growth reached a plateau phase after 8 days and the extent of angiogenesis overlapped that produced by the 200 ng/pellet FGF-2 ( Fig. 1A) . A 10-fold lower concentration of TSP-1 produced angiogenesis with a delayed pattern of capillary progression and whose extent at the maximum reproduced 60% of the activity given by 2 µg/pellet. At 20 ng/pellet TSP-1 elicited the budding of few capillaries at 8 days after implant, which rapidly regressed.
To assess the specificity of TSP-1 effect on angiogenesis, the molecule was incorporated with ammonium-sulfate precipitated anti-TSP-1 antibodies (5 µg/pellet). The addition of anti-TSP-1 antibodies abrogated angiogenesis induced by TSP-1, while the antibody itself had no effect (Table 1) . Moreover, heat inactivation of TSP-1 reduced its angiogenic activity (data not shown). Since TSP-1 copurifies with TGF-β (31), we checked whether the pro-angiogenic activity of TSP-1 was due to trace amount of the growth factor present in TSP-1 preparation. The presence of neutralizing anti TGF-β antibody (1 µg/pellet) did not change angiogenesis induced by 2 µg/pellet TSP-1 (n=4 animals).
Previous studies indicated that TSP-1 could potentiate FGF-2-induced angiogenesis by an inflammatory mechanism (34) . In our experiments the angiogenesis elicited by TSP-1 was not associated with any inflammatory response, as evidenced by histological analysis (Fig. 1B, C) . We next assessed whether TSP-1 effect could be ascribed to the presence of trace amount of FGF-2 in TSP preparation or to the displacement of FGF-2 from matrix store within the corneal stroma. These possibilities were excluded since anti-FGF-2 antibody added to TSP-1 preparation did not modify TSP-1-induced angiogenic effect (70% of positive implants for TSP-1 in the presence of anti-FGF-2 antibody, versus 80% of positive implants for TSP-1 alone, n=6).
TSP-1 becomes anti-angiogenic in the presence of FGF-2
TSP-1 activity in the presence of FGF-2 has been controversial. In rat corneas it inhibits FGF-2 angiogenic activity (25, 27) , while in rabbit corneas it has been reported to potentiate FGF-2 as well as LPS-induced angiogenesis by an inflammatory mechanism (34) . We assessed the effect of TSP-1 on angiogenesis driven by FGF-2 via a non-inflammatory manner. Pellets were prepared containing TSP-1 (200 ng and 2 µg) and FGF-2 (200 ng). In agreement with previous findings, in our experimental conditions the addition of TSP-1 to pellets sequestering FGF-2, dose-dependently blocked the angiogenic effect of FGF-2. TSP-1 at 2 µg completely abrogated the ability of FGF-2 to elicit capillary growth in corneas that remained totally avascular and transparent, while 200 ng/pellet TSP-1 reduced by 50% the effect of FGF-2 ( Fig. 2A) . We previously reported that TSP-1 binds to FGF-2 (28) . In order to exclude that the formation of a TSP-1/FGF-2 complex might hinder the diffusion of the angiogenic factor, we measured the release of radiolabeled FGF-2 from Elvax pellets in the presence of TSP-1. TSP-1 did not affect the release of FGF-2 from the pellets (Fig. 2B) . Inhibition of angiogenesis was also observed when TSP-1 (2 µg/pellet) and FGF-2 (200 ng/pellet) were tested in the cornea in two separate pellets, further demonstrating that no direct interaction between the two molecules within the pellet existed as a mechanism for inhibition (data not shown).
Moreover, in experiments in which FGF-2 activity was evaluated in the presence of anti-TSP-1 antibody, the inhibitory effect of endogenous TSP was further reinforced by the observation that the progression of FGF-2-induced capillaries was potentiated (Fig. 2C) .
The 25 and 140 kDa TSP-1 fragments have opposite activity on in vivo angiogenesis
In vitro studies have indicated that different structural domains of the modular TSP-1 molecule exert different functions on cultured endothelium (22) (23) (24) (25) (26) 28, 32) . To identify which domain of TSP-1 was responsible for in vivo angiogenesis, the 25 kDa and 140 kDa fragments of TSP-1 were tested in the rabbit cornea assay. The two proteins were assayed at the concentration equimolar with 2 µg TSP-1, either alone or in the presence of 200 ng FGF-2. The heparin binding 25 kDa fragment (285 ng/pellet) elicited a strong angiogenic response with 100% of the implants producing angiogenesis. The extent of the response was even stronger than the one induced by the equimolar concentration of TSP-1 per se (Fig. 3A,B) . The 25 kDa fragment-promoted angiogenesis was not affected by the addition of anti-FGF-2 antibody (n=3), excluding the contribution of endogenous FGF-2. In contrast, the 140 kDa carboxy-terminal fragment tested alone (1.5 µg/pellet) was devoid of any angiogenic activity (Fig. 3A,C) .
The 25 kDa fragment was not inhibitory to FGF-2 activity, but on the contrary further sustained the angiogenic response of FGF-2 (200 ng/pellet), leading to a greater number of rapidly progressing capillaries (Fig. 4A) . The final extent of the angiogenic response produced by the combination of the two factors, however, was similar to the one produced by the 25 kDa domain per se, indicating that the dynamics of the angiogenic response and not the total extent of vascular growth was improved. On the contrary, the 140 kDa fragment blocked the neovascular response induced by FGF-2 (Fig. 4B ). These results demonstrate that the 25 kDa fragment is responsible for the pro-angiogenic activity of TSP-1, while the 140 kDa retains the angiosuppressive effect of the molecule.
TSP-1 and its pro-angiogenic fragment increase invasiveness of endothelial cells
We next investigated the mechanisms by which TSP-1 and its 25 kDa fragment might induce pro-angiogenic activities on endothelial cells in vitro. TSP-1 was evaluated for its capacity to induce the invasiveness of different endothelial cell types such as bovine aortic endothelial cells (BAEC) and human endothelial cells, isolated from large (HUVEC) or small vessels (HAMEC). Induction of invasion by TSP-1 was dose-dependent ( Fig. 5A) , and, in all cases, the stimulation was comparable to that of FGF-2 (Fig. 5B) . Heparin, which binds to the 25 kDa fragment with high affinity, strongly prevented TSP-1-induced invasion of endothelial cells ( Table 2 ), indicating that the heparin binding domain of TSP-1 is involved in this activity. In agreement with in vivo data, the 25 kDa fragment of TSP-1 induced endothelial cell invasiveness at a degree comparable to equimolar concentration of TSP-1 (Fig. 5C ). Similar results were obtained when the heparin binding fragment was obtained by enzymatic digestion of TSP-1 with thrombin or chymotrypsin. In contrast, the 140 kDa fragment did not induce endothelial cell invasion (data not shown) 
Production of MMP-2 and TIMP-2 by endothelial cells is differentially regulated by TSP-1 and its proteolytic fragments
TSP-1 can induce the production of the matrix metalloproteinase MMP-9 in endothelial cells (32) . Endothelial cell invasiveness induced by TSP-1 was prevented by inhibitors of matrix metalloproteinase, like BB-94 and 1,10-Phenanthrolene (Table 2 ) (47). Subconfluent cultures of postcapillary venular endothelial cells (CVEC) were exposed for 24 hr to TSP-1 or to the two fragments to assess gelatinase production. Gelatin zymography of control supernatants showed the constitutive release of the latent form of MMP-2, visualized as a band at 72 kDa (Fig. 6A) . TSP-1 (25-110 nM) dose-dependently stimulated the release of MMP-2 and induced its activation as revealed by the appearance of the 67 kDa form (Fig. 6A) . Furthermore, TSP-1 induced the production of the 92 kDa gelatinase MMP-9 (Fig. 6A) . Consistent with the results in the invasion assay, the 25 kDa fragment increased both latent and activated MMP-2, and induced MMP-9 (Fig. 6B) . The heparin binding domain released from TSP-1 by either thrombin or chymotrypsin was equally active (not shown). The 140 kDa fragment showed a stimulatory effect on MMP-9 production; however, it did not affect MMP-2 production nor activation (Fig. 6B ).
Since gelatinase activity is the final result of the balance between MMPs and their physiological inhibitors TIMPs (48), we assessed the ability of TSP-1 and its fragments to affect the expression of TIMP-2, the main inhibitor of MMP-2 activity. Cells were exposed for 8 hr to equimolar concentration (110 nM) of TSP-1, its 25 and 140 kDa fragments and RNA extracted. Analysis of RT-PCR amplification products showed that the 140 kDa induced a twofold increase in the expression of TIMP-2, while the 25 kDa reduced by 50% its constitutive expression (Fig. 7) . TSP-1 did not significantly affect TIMP-2 expression. This finding indicates that the two fragments affect the proteolytic balance of endothelial cells in opposite ways.
To assess whether the 140 kDa fragment could counteract the proinvasive behavior of TSP-1, endothelial cells were pretreated with the fragment before exposure to TSP-1 or to FGF-2. Preincubation with 110 nM of the 140 kDa fragment prevented the increase in both MMP-2 and MMP-9 production induced by 110 nM TSP-1 or 10 ng/ml FGF-2 (Table 3) , and resulted in the complete inhibition of endothelial cell chemoinvasion stimulated by the same concentrations of TSP-1 and FGF-2 (100% inhibition; P<0.05 compared to untreated cells, n=3). 
DISCUSSION
The present study demonstrates that TSP-1 promotes angiogenesis when dismissed in the avascular corneal stroma of albino rabbits, but exerts inhibitory activity when angiogenesis is induced in the same tissue by FGF-2. The observed dual behavior of TSP-1 is produced by domains with opposite functions that also differ in terms of ability to activate degradative and invasive behavior of vascular endothelium. The heparin binding 25 kDa fragment is responsible for the angiogenic activity of the whole molecule, potentiates angiogenesis induced by FGF-2, and increases MMP-2 and MMP-9 production in endothelium, while down-regulating TIMP-2 expression. Conversely, the 140 kDa fragment lacks any proangiogenic activity, up-regulates TIMP-2 expression, counteracts TSP-1 pro-invasive activity and inhibits FGF-2-induced angiogenesis. Thus, TSP-1 should be regarded as a dual regulator in the angiogenesis process whose function may be shifted by the local metabolism and/or availability of its proteolytic products.
The angiogenic effect of TSP-1 reported here is specific and is comparable to the response obtained with the angiogenic factor FGF-2. The molecular mechanisms involved in the regulation of angiogenesis by TSP-1 still need to be elucidated. Interaction of TSP-1 with the receptor CD36 on endothelial cells (35) and with soluble angiogenesis regulatory factors (28) (29) (30) (31) or enzymes (37,38) might contribute to the anti-angiogenic activity of TSP-1 (20) . We demonstrated that TSP-1 binds specifically to FGF-2 (28). However, the inhibitory effect of TSP-1 in the rabbit cornea is not due to its sequestration of FGF-2 within the pellet, since the release of FGF-2 is not modified by the addition of TSP-1. In this study, we show that a 1:1 ratio in the number of molecules of monomeric TSP-1 and FGF-2 results in the reciprocal neutralization of the angiogenic activity.
The pro-angiogenic activity of TSP might be caused either by a direct activation of proangiogenic functions on endothelial cells, or through the activation of accessory cells. The outgrowth of capillary structures induced by TSP-1 in the model of the aortic ring in a fibrin or collagen gel has been explained as an indirect stimulation of aortic myofibroblasts, which, in turn, release soluble angiogenic factors (33) . Accordingly, TSP-1 has been reported to stimulate the proliferation of smooth muscle cells, mesangial cells and fibroblasts, alone or by potentiating the activity of PDGF and epidermal growth factor (EGF) (20) . BenEzra attributed the potentiation of angiogenesis by TSP-1 to the inflammatory cells, particularly polymorphonuclear cells recruited by TSP-1, which heavily infiltrated the cornea (34) . In the present study, no sign of inflammatory infiltrate has been detected, thus ruling out the possibility of an indirect effect. TSP-1 promoted angiogenesis is due to a FGF-2-independent mechanism, since anti-FGF-2 antibodies did not modify TSP-1-induced angiogenesis. The potential contribution of TGF-β contamination can also be excluded by the lack of effect of anti TGF-β neutralizing antibodies on TSP-1-induced angiogenesis and by the fact that the TGF-β binding/activating sites have been localized in the 140 kDa fragment, endowed with anti-angiogenic activity (31).
TSP-1 can be visualized as a sequence of structural domains, each endowed with the ability to specifically bind to different cell receptors, heparin, matrix components, growth factors and cytokines, proteolytic enzymes, Ca 2+ (20) . In the rabbit cornea the 140 kDa fragment, itself inactive, is a potent inhibitor of FGF-2-induced angiogenesis. This finding is consistent with other studies, which provided strong evidence that the anti-angiogenic domain of TSP-1 is located within this fragment (26-28,35,36) . On the contrary, our findings provide the first evidence that the other fragment of TSP-1, the 25 kDa heparin binding fragment, is the angiogenic domain of TSP-1. Consistent with the existence of domains with opposite functions within the TSP-1 molecule, we found that the 25 kDa fragment is more efficient than TSP-1 in promoting angiogenesis in vivo and potentiates FGF-2 effect. Although we cannot exclude the occurrence of conformational changes, the in vitro data suggest that the two domains within the whole TSP-1 molecule modulate and neutralize each other's function, an event likely to occur also in vivo. Thus, the 140 kDa fragment, i.e. the inhibitory domain, is responsible for the reduced angiogenesis expressed by the whole TSP-1 molecule when compared to the 25 kDa peptide.
TSP-1 has been reported to stimulate several pro-angiogenic activities of endothelial cells in vitro. Most of these activities are retained by the heparin binding, 25 kDa fragment of TSP-1, in agreement with our in vivo findings. TSP-1 and the 25 kDa fragment induce endothelial cell adhesion and migration (24, 27, 36) . Recently, it has been shown that TSP-1 induces the production of the matrix metalloproteinase MMP-9 by bovine aortic endothelial cells, thus increasing their ability to invade (32) . Induction of MMP-9 was inhibited by both the CSVTCG peptide and by heparin, suggesting that both the CSVTCG and the heparin binding domain of TSP are involved in this process (32) . In agreement, we found that TSP-1 stimulates the ability of several endothelial cell types to invade and degrade the extracellular matrix. Moreover, we show that TSP-1 and its fragments regulate the degradative capacity of endothelial cells by acting on MMPs at three levels: transcription, conversion of the proenzyme into the active form and synthesis of the specific inhibitor. The 25 kDa fragment induced endothelial cell invasiveness and MMP-2 and MMP-9 activities. The increase in MMPs activity was paralleled by a down-regulation of TIMP-2 expression, thus resulting in a shift of the proteases/inhibitors balance towards proteolysis. The 140 kDa fragment, although able to induce MMP-9, did not affect MMP-2 and was a potent stimulator of TIMP-2. The resulting effect was anti-invasive: indeed, we found that the 140 kDa not only did not induce invasiveness of endothelial cells, but also counteracted the proinvasive activity of TSP-1. The activity of the whole TSP-1 molecule on MMPs/TIMP-2 production by endothelial cells appears to be the sum of the different effects of the two fragments. The increase in MMP-2 and MMP-9 production reflects the positive effect of one (MMP-2) or both fragments (MMP-9). The lack of effect of TSP-1 on TIMP-2 production might reflect the mutual neutralization of the opposite activity of the two fragments.
The 25 kDa fragment is characterized by a strong affinity for heparin. Whether the interaction with heparin or such heparin-like molecules as the heparan sulfate proteoglycans (HSPG) is required for the angiogenic activity is not clear. This domain of TSP-1 has been described as interacting with other cell receptors, insensitive to heparinases and thus probably different from HSPG (49) , which also include members of the LDL receptor family (50). We cannot rule out the possible role of other, not yet identified, endothelial cell receptors for the 25 kDa fragment.
The biological meaning of the dual role of TSP-1 in angiogenesis might rely on the environmental setting, as demonstrated for other angiogenic modulators (40) . Depending on which part of the molecule is available and/or functional in a given setting, the resulting effect on angiogenesis will differ (Fig. 8) . The availability of distinct TSP-1 domains might depend on the association of TSP-1 with other molecules able to mask other sites of the molecule or to induce steric changes. An example of this phenomenon is provided by the divergent effect of TSP-1 on the proliferation of endothelial cells depending on whether TSP is substrate-bond or soluble (33) . Alternatively, fragments of TSP-1 might be synthesized or released in vivo by proteolysis of the molecule. No proof of alternative splicing of TSP has been published, thus the lower molecular weight forms of TSP are likely to be generated by proteolysis of the intact molecule (20) . Evidence of the presence of TSP-1 fragments in vivo has been reported. In the serum of patients with amyotrophic lateral sclerosis, ELISA and Western blot analysis showed a decrease in TSP and an increase in the amount of proteolytic fragments, consistent with an increased proteolytic activity in this pathology (51). Moreover, the first indication of the anti-angiogenic activity of TSP-1 was the identification of the 140 kDa fragment as the inhibitor of angiogenesis in a model of transformed hamster cells (25) .
Angiogenesis is a complex phenomenon resulting from balance among positive and negative regulators. Redundancy justifies the contradictory or not clear-cut data from FGF-2 and TSP-1 knockout mice (52-54). The overall effect of TSP on angiogenesis depends on the biological context in which TSP-1 acts: presence of different cell types, receptors and angiogenic factors, the ionic milieu, presence of heparin-like molecules, whether TSP is soluble or matrix bound (20) . These results contribute to the new concept in angiogenesis that a single molecule can encode both angiogenic and anti-angiogenic peptides, as recently reported for prolactin (55). Our findings demonstrate that the final outcome of TSP-1 effect on angiogenesis depends on its local metabolism, which makes available smaller mediators that affect endothelial cell functions and modulate the MMP/TIMP balance in opposite ways. 
